Get the Stockscreener App
0.8461
0.82%
-0.007
After Hours:
.86
0.0139
+1.64%
Pds Biotechnology Corp stock is traded at $0.8461, with a volume of 286.04K.
It is down -0.82% in the last 24 hours and down -17.05% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
See More
Previous Close:
$0.8531
Open:
$0.8588
24h Volume:
286.04K
Relative Volume:
0.29
Market Cap:
$47.23M
Revenue:
-
Net Income/Loss:
$-33.36M
P/E Ratio:
-1.2617
EPS:
-0.6706
Net Cash Flow:
$-23.09M
1W Performance:
-5.89%
1M Performance:
-17.05%
6M Performance:
-6.78%
1Y Performance:
-36.38%
1-Day Range:
$0.8347
$0.89
1-Week Range:
$0.8202
$0.9134
52-Week Range:
$0.5068
$1.55
Pds Biotechnology Corp Stock (PDSB) Company Profile
Name
Pds Biotechnology Corp
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.8461 | 49.18M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corp Stock (PDSB) Latest News
PDSB | PDS Biotechnology Corporation Common Executive Compensation - Quiver Quantitative
PDS Biotechnology Corp (PDSB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay - Stock Titan
PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB) - TradingView
PDS Biotechnology Corp. Actuals & Estimates (DUS:EU6) - TradingView
PDSB Forecast — Price Target — Prediction for 2027 - TradingView
PDS Biotech’s Double Squeeze: Nasdaq Clock Ticking as Equity Dilution Looms - AD HOC NEWS
PDS Biotechnology Corp (PDSB) Institutional Confidence - TradingKey
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PDS Biotechnology Corp (PDSB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PDS Biotechnology Corp (PDSB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDS Biotechnology Corp (PDSB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PDS Biotechnology Corp (PDSB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PDS Biotechnology Closes Financing and Retires Convertible Debentures - TipRanks
PDS Biotechnology (NASDAQ: PDSB) launches $50M ATM program tied to YA II financing - Stock Titan
[PRE 14A] PDS Biotechnology Corp Preliminary Proxy Statement - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program - Stock Titan
PDS Biotechnology schedules 2026 annual meeting for Aug. 10; stockholder proposal deadline set - TradingView
PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff - Stock Titan
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - MSN
Should I buy PDS Biotechnology (PDSB) - Zacks Investment Research
PDS Biotechnology Corporation - MLQ.ai
PDS Biotechnology Stock Gets Nasdaq Extension as Traders Eye PDSB - Bez Kabli
PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule - Stock Titan
PDS Biotechnology (PDSB) Slides 3.6% as Stock Tests Key Support Near $1.02Breakaway Gap - The Legal Advocate
PDSB Q4 2025 Earnings Call Transcript - Yahoo Finance
PDS Biotechnology Q1 2026 Earnings: EPS Beat on Narrower Loss, Clinical Progress in FocusReturn On Capital - Newser
PDS Biotechnology Q1 2026 Earnings: Narrowed Loss Per Share and Clinical Progress Drive Positive Market ResponseGrowth Acceleration Report - thelegaladvocate.com
PDS Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 3.45%Earnings Growth Forecast - Newser
PDS Biotechnology Q1 2026 Earnings: EPS Beat Highlights Progress Despite Pre-Revenue StatusEarnings Forecast Report - newsline.com
PDS (PDSB) Q1 2026 Beat: Revenue $N/A, EPS Exceeds by SignificantPositive Surprise Momentum - The Legal Advocate
ETFs Investing in PDS Biotechnology Corp. Stocks - TradingView
PDS Biotechnology Q1 2026 earnings preview - MSN
Number of shareholders of PDS Biotechnology Corp. – SWB:EU6 - TradingView
PDS Biotechnology: Juni-Test für Wandelanleihe - kapitalmarktexperten.de
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corp reports results for the quarter ended March 31Earnings Summary - TradingView
PDS Biotechnology (PDSB) posts Q1 2026 loss and plans costly debt redemption - Stock Titan
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript - Sahm
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients - MSN
PDSB Q1 2026 Earnings Transcript - AOL.com
PDS Biotechnology Q1 Earnings Call Highlights - MarketBeat
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
PDS Biotech Reports Q1 2026 Financial Results, Highlights Clinical Progress in Cancer Immunotherapy Trials - Minichart
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
PDSB: Protocol changes accelerate clinical timelines and reduce costs, with improved financials - TradingView
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations - Investing.com
PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5% - ChartMill
PDS Biotechnology posts quarterly financial results and updates clinical programs - Traders Union
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings - Quiver Quantitative
Pds Biotechnology Corp Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):